Physician profile
Jose E Igoa
NPI 1780615732
$820,852.29
in general payments reported to CMS, 2019-2025
35 companies · $102K in 2025
The $102K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $70K · 2020: $63K · 2021: $125K · 2022: $149K · 2023: $166K · 2024: $145K · 2025: $102K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $331K · Consulting Fee: $33K · Travel and Lodging: $23K · Food and Beverage: $20K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $4,000 · Honoraria: $3,875 · Education: $70.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $330,812.00 |
| Consulting Fee | $32,749.00 |
| Travel and Lodging | $22,691.86 |
| Food and Beverage | $19,657.03 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $4,000.00 |
| Honoraria | $3,875.00 |
| Education | $70.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $329,228.68 | 2021-2025 | |
| Alkermes, INC. | $100,508.91 | 2019-2025 | Lybalvi, Aristada, Aristada Initio |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $94,024.26 | 2020-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $59,456.44 | 2019-2025 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $57,765.23 | 2021-2025 | Qelbree, Qelbree |
| Allergan, INC. | $46,824.61 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $31,930.26 | 2019-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Ironshore Pharmaceuticals INC. | $28,481.00 | 2019-2024 | Jornay Pm |
| Axsome Therapeutics, INC. | $20,446.12 | 2022-2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $19,798.70 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Vanda Pharmaceuticals INC. | $14,125.74 | 2024-2025 | Fanapt |
| E.R. Squibb & Sons, L.L.C. | $10,794.37 | 2024-2025 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $1,744.37 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $1,287.65 | 2023 | Quviviq |
| Lundbeck LLC | $737.74 | 2020-2025 | Rexulti |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $656.59 | 2019-2024 | Trintellix |
| Corium, LLC | $554.49 | 2021-2025 | Azstarys, Adlarity |
| Janssen Pharmaceuticals, INC | $510.65 | 2019-2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $446.15 | 2019-2025 | Rexulti, Abilify Asimtufii |
| Acadia Pharmaceuticals INC | $291.01 | 2021-2023 | Nuplazid |
| Indivior INC. | $273.17 | 2019-2024 | Perseris |
| Tris Pharma INC | $240.05 | 2019-2025 | Dyanavel Xr, Onyda Xr |
| Eisai INC. | $228.01 | 2020-2022 | |
| Mdd US Operations, LLC | $106.77 | 2019 | |
| Collegium Pharmaceutical, INC. | $96.33 | 2025 | Jornay Pm |
| Merck Sharp & Dohme LLC | $84.73 | 2020-2023 | Belsomra |
| Shire North American Group INC | $48.42 | 2019 | |
| Arbor Pharmaceuticals, INC. | $40.58 | 2019-2021 | |
| Almatica Pharma LLC | $25.53 | 2021 | |
| Phadia US INC. | $19.61 | 2022 | |
| Xeris Pharmaceuticals, INC. | $16.50 | 2022 | |
| Jazz Pharmaceuticals INC. | $16.12 | 2021 | |
| Biogen, INC. | $15.74 | 2021 | |
| Avanir Pharmaceuticals, INC. | $13.89 | 2020 | |
| Neuronetics, INC. | $13.87 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Igoa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.